Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAG-HSV1716
- Development stage
- Preclinical
- Lead developer
- University of Sheffield
- Modality
- Nanoparticles → Drug Delivery Systems, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
MAG-HSV1716 is a preclinical-stage magnetized oncolytic virus therapy developed by the University of Sheffield in collaboration with Virttu Biologics. It consists of the oncolytic herpes simplex virus strain 1716 (HSV1716) co-assembled via electrostatic interactions with biocompatible magnetic nanoparticles (MAG) derived from the magnetotactic bacterium *Magnetospirillum magneticum* (AMB-1). This magnetization shields the virus from neutralizing antibodies in the circulation and, when combined with external magnetic guidance, enhances systemic delivery and tumor targeting. Upon reaching the tumor, MAG-HSV1716 selectively infects and lyses cancer cells, inducing immunogenic cell death (ICD) and promoting antitumor immunity. It is being investigated for the treatment of solid tumors, particularly breast cancer.
- Other names
- MAG-OVmagnetized HSV1716
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)PCNA (Proliferating cell nuclear antigen)
Beyond the preview
Go deeper on MAG-HSV1716.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAG-HSV1716.